The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.
Tolmacheva V.A.
Sechenov First Moscow State Medical University (Sechenov University)
Parfenov V.A.
Sechenov First Moscow State Medical University
Ostroumova T.M.
Sechenov First Moscow State Medical University (Sechenov University)
Nodel M.R.
Sechenov First Moscow State Medical University (Sechenov University)
Romanov D.V.
Sechenov First Moscow State Medical University (Sechenov University);
Mental Health Research Center
Mental disorders in blepharospasm
Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2023;123(12): 76‑82
Views: 1100
Downloaded: 9
To cite this article:
Tolmacheva VA, Parfenov VA, Ostroumova TM, Saloukhina NI, Nodel MR, Romanov DV. Mental disorders in blepharospasm. S.S. Korsakov Journal of Neurology and Psychiatry.
2023;123(12):76‑82. (In Russ.)
https://doi.org/10.17116/jnevro202312312176
To analyze mental disorders in blepharospasm (BS) before and after botulinum therapy (BT).
We examined 25 patients with BS (9 men and 16 women), aged 50 to 85 years (mean 64.1±18.5), with BS (main study group). The control group consisted of 20 healthy individuals (7 men and 13 women, mean age 63.5±8.5). Patients were examined before and after BT (after 3 weeks) using a diagnostic structured interview Mini International Neuropsychiatric Interview, GAD-7, PHQ-9, fear of negative assessment (short version) and The Liebowitz Social Anxiety Scale (LSAS).
Fifty-six percent of patients with BS, as assessed by the GAD-7, showed a high level of anxiety, while depression, measured by the PHQ-9 and found in 52% of patients, was mainly manifested by mild disorders. In the group of patients with BS, the mean scores were higher on the GAD-7, PHQ-9, fear of negative assessment (p<0.001) and LSAS (p<0.05) than in the control group. After treatment with BT, the levels of anxiety and depression in patients with BS decreased slightly and remained higher compared with the control group. Psychiatric examination in the majority (64%) of patients revealed mental disorders that could not be explained by the occurrence of BS. The remaining 36% of patients had adaptation disorders (nosogenic reactions) caused by BS. Affective mental pathology (recurrent depressive disorder and dysthymia) and anxiety disorders (social phobia and adjustment disorders) were more often observed in the main study group compared with the control group (24% versus 5% and 68% versus 10%, respectively).
A significant proportion of patients with BS have anxiety and depressive disorders, the severity of which does not depend only on the severity of motor symptoms and does not significantly decrease after successful BT, but is caused by mental disorders that preceded the manifestation of BS. Identification of mental disorders to varying degrees associated with BS, not only on the basis of psychometric scales, but also consultation with a psychiatrist, will allow, in addition to the correction of motor symptoms of BS, to differentiate the therapeutic approach through psychotherapy and psychopharmacotherapy.
Keywords:
Authors:
Tolmacheva V.A.
Sechenov First Moscow State Medical University (Sechenov University)
Parfenov V.A.
Sechenov First Moscow State Medical University
Ostroumova T.M.
Sechenov First Moscow State Medical University (Sechenov University)
Nodel M.R.
Sechenov First Moscow State Medical University (Sechenov University)
Romanov D.V.
Sechenov First Moscow State Medical University (Sechenov University);
Mental Health Research Center
Received:
12.01.2023
Accepted:
28.08.2023
List of references:
Close metadata
Email Confirmation
An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.
Email Confirmation
Log in to the site using your account in one of the services
We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.